Overview SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary A mono centre study to evaluate the efficacy of SOM230 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer. Phase: Phase 2 Details Lead Sponsor: Federico II UniversityTreatments: EverolimusPasireotideSirolimus